Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls

Bhargava, 2007, Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity, Am J Clin Pathol, 127, 103, 10.1309/TDP92PQLDE2HLEET Luo, 2013, Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas, Hum Pathol, 44, 1241, 10.1016/j.humpath.2012.10.009 Conner, 2015, Metastatic carcinoma of unknown primary: diagnostic approach using immunohistochemistry, Adv Anat Pathol, 22, 149, 10.1097/PAP.0000000000000069 Krings, 2014, Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer, Hum Pathol, 45, 2225, 10.1016/j.humpath.2014.06.022 Asch-Kendrick, 2016, The role of GATA3 in breast carcinomas: a review, Hum Pathol, 48, 37, 10.1016/j.humpath.2015.09.035 Kouros-Mehr, 2006, GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland, Cell, 127, 1041, 10.1016/j.cell.2006.09.048 Miettinen, 2014, GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors, Am J Surg Pathol, 38, 13, 10.1097/PAS.0b013e3182a0218f Cimino-Mathews, 2013, GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas, Hum Pathol, 44, 1341, 10.1016/j.humpath.2012.11.003 Mollaaghababa, 2003, The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia, Oncogene, 22, 3024, 10.1038/sj.onc.1206442 Miettinen, 2015, Sox10-a marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors, Am J Surg Pathol, 39, 826, 10.1097/PAS.0000000000000398 Nonaka, 2008, Sox10: a pan-schwannian and melanocytic marker, Am J Surg Pathol, 32, 1291, 10.1097/PAS.0b013e3181658c14 Cimino-Mathews, 2013, Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas, Hum Pathol, 44, 959, 10.1016/j.humpath.2012.09.005 Qazi, 2020, Combined use of SOX10 and GATA3 in mammary carcinoma, Pathol Res Pract, 216, 152801, 10.1016/j.prp.2019.152801 Jamidi SK, Hu J, Aphivatanasiri C, Tsang JY, Poon IK, Li JJ, et al. SOX10 as a sensitive marker for triple negative breast cancer. Histopathology. 2020. Online ahead of print. Tozbikian, 2019, A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer, Hum Pathol, 85, 221, 10.1016/j.humpath.2018.11.005 Dwarakanath, 1987, S-100 protein positivity in breast carcinomas: a potential pitfall in diagnostic immunohistochemistry, Hum Pathol, 18, 1144, 10.1016/S0046-8177(87)80382-9 DeLair, 2013, Non-mammary metastases to the breast and axilla: a study of 85 cases, Mod Pathol, 26, 343, 10.1038/modpathol.2012.191 Cimino-Mathews A, Harvey S, Argani P. Metastases to the breast. In: Shin S, editor. A comprehensive guide to needle core biopsies of the breast. Switzerland: Springer International Publishing; 2016. Park, 2007, Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma, Arch Pathol Lab Med, 131, 1561, 10.5858/2007-131-1561-POIMHD Dennis, 2005, Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm, Clin Cancer Res, 11, 3766, 10.1158/1078-0432.CCR-04-2236 Lee AHS, Hodi Z, Soomro I, Sovani V, Abbas A, Rakha E, et al. Histological clues to the diagnosis of metastasis to the breast from extramammary malignancies. Revised version. Histopathology. 2020. Epub ahead of print. Miettinen, 2001, Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers, Am J Surg Pathol, 25, 205, 10.1097/00000478-200102000-00008 Nelson, 2017, Utility of Sox10 labeling in metastatic breast carcinomas, Hum Pathol, 67, 205, 10.1016/j.humpath.2017.08.011 Montagnese, 2004, Granular cell tumor of the breast, Am Surg, 70, 52, 10.1177/000313480407000112 Robens, 2010, Thyroid transcription factor-1 expression in breast carcinomas, Am J Surg Pathol, 34, 1881, 10.1097/PAS.0b013e3181f884e8 Tornos, 2005, Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary, Am J Surg Pathol, 29, 1482, 10.1097/01.pas.0000176429.88702.36 Domfeh, 2008, WT1 immunoreactivity in breast carcinoma: selective expression in pure and mixed mucinous subtypes, Mod Pathol, 21, 1217, 10.1038/modpathol.2008.69 Nonaka, 2008, Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas, Am J Surg Pathol, 32, 1566, 10.1097/PAS.0b013e31816d71ad Kilgore, 2019, Unexpected PAX8 immunoreactivity in metastatic high-grade breast cancer, Appl Immunohistochem Mol Morphol, 27, 637, 10.1097/PAI.0000000000000707 Gurel, 2010, NKX3.1 as a marker of prostatic origin in metastatic tumors, Am J Surg Pathol, 34, 1097, 10.1097/PAS.0b013e3181e6cbf3 Asch-Kendrick, 2014, NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas, J Clin Pathol, 67, 768, 10.1136/jclinpath-2014-202272 Werling, 2003, CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas, Am J Surg Pathol, 27, 303, 10.1097/00000478-200303000-00003 Ritterhouse, 2019, Loss of SMAD4 protein expression in gastrointestinal and extra-gastrointestinal carcinomas, Histopathology, 75, 546, 10.1111/his.13894 Arpino, 2002, Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome, Cancer, 94, 2119, 10.1002/cncr.10455 Persson, 2009, Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck, Proc Natl Acad Sci USA, 106, 18740, 10.1073/pnas.0909114106 Kim, 2018, MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene, J Pathol, 244, 143, 10.1002/path.5006 Poling, 2017, MYB labeling by immunohistochemistry is more sensitive and specific for breast adenoid cystic carcinoma than MYB labeling by FISH, Am J Surg Pathol, 41, 973, 10.1097/PAS.0000000000000878 Del Castillo, 2015, Secretory breast carcinoma: a histopathologic and genomic spectrum characterized by a joint specific ETV6-NTRK3 gene fusion, Am J Surg Pathol, 39, 1458, 10.1097/PAS.0000000000000487 Tognon, 2002, Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma, Cancer Cell, 2, 367, 10.1016/S1535-6108(02)00180-0 Cocco, 2018, NTRK fusion-positive cancers and TRK inhibitor therapy, Nat Rev Clin Oncol, 15, 731, 10.1038/s41571-018-0113-0 Hechtman, 2017, Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions, Am J Surg Pathol, 41, 1547, 10.1097/PAS.0000000000000911 Harrison, 2019, Pan-TRK immunohistochemistry: a useful diagnostic adjunct for secretory carcinoma of the breast, Am J Surg Pathol, 43, 1693, 10.1097/PAS.0000000000001366 Chiang, 2016, IDH2 mutations define a unique subtype of breast cancer with altered nuclear polarity, Cancer Res, 76, 7118, 10.1158/0008-5472.CAN-16-0298 Lozada, 2018, Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort, Histopathology, 73, 339, 10.1111/his.13522 Yan, 2009, IDH1 and IDH2 mutations in gliomas, N Engl J Med, 360, 765, 10.1056/NEJMoa0808710 Pareja, 2020, Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity, Mod Pathol, 33, 1056, 10.1038/s41379-019-0442-2 Alsadoun, 2018, Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases, Mod Pathol, 31, 1367, 10.1038/s41379-018-0047-1 Cottrell, 2018, PD-L1 and emerging biomarkers in immune checkpoint blockade therapy, Cancer J, 24, 41, 10.1097/PPO.0000000000000301 Walk, 2020, The cancer immunotherapy biomarker testing landscape, Arch Pathol Lab Med, 144, 706, 10.5858/arpa.2018-0584-CP Taube, 2018, Implications of the tumor immune microenvironment for staging and therapeutics, Mod Pathol, 31, 214, 10.1038/modpathol.2017.156 List of cleared or approved companion diagnostic devices (in vitro and imaging tools). U.S. Food and Drug Administration (FDA). 2020. https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools. Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367:eaax0182. Lu, 2019, Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis, JAMA Oncol, 5, 1195, 10.1001/jamaoncol.2019.1549 Narayan, 2020, FDA approval summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1, Clin Cancer Res, 26, 2284, 10.1158/1078-0432.CCR-19-3545 Malhotra MK, Emens LA. The evolving management of metastatic triple negative breast cancer. Semin Oncol. 2020;47:229–37. Schmid, 2018, Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer, N Engl J Med, 379, 2108, 10.1056/NEJMoa1809615 Cortes, 2020, KEYNOTE-355: randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer, J Clin Oncol, 38, 1000, 10.1200/JCO.2020.38.15_suppl.1000 Schmid, 2020, Pembrolizumab for early triple-negative breast cancer, N Engl J Med, 382, 810, 10.1056/NEJMoa1910549 Scheerens, 2017, Current status of companion and complementary diagnostics: strategic considerations for development and launch, Clin Transl Sci, 10, 84, 10.1111/cts.12455 Ventana PD-L1 (SP142 Assay) Interpretation guide for triple-negative breast carcinoma (TNBC). Ventana Medical Systems, Inc. and Roche Diagnostics International, Inc. 2019. https://diagnostics.roche.com/us/en/landing-pages/guide-tnbc-therapy-decisions-with-confidence.html. Cimino-Mathews, 2016, PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas, Hum Pathol, 47, 52, 10.1016/j.humpath.2015.09.003 Cimino-Mathews, 2013, Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study, Hum Pathol, 44, 2055, 10.1016/j.humpath.2013.03.010 Szekely, 2018, Immunological differences between primary and metastatic breast cancer, Ann Oncol, 29, 2232, 10.1093/annonc/mdy399 Li, 2018, Abstract PD6-01: prevalence of PDL1 and tumor infiltrating lymphocytes (TILs) in primary and metastatic TNBC, Cancer Res, 78, PD6-01, 10.1158/1538-7445.SABCS17-PD6-01 Rimm, 2019, Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer, Breast Cancer Res, 21, 10.1186/s13058-019-1156-6 Rimm, 2017, A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer, JAMA Oncol, 3, 1051, 10.1001/jamaoncol.2017.0013 Reisenbichler ES, Han G, Bellizzi A, Bossuyt V, Brock J, Cole K, et al. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Mod Pathol. 2020;33:1746–52. Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey J-M, et al. Development of a PD-L1 complementary diagnostic immunohistochemistry assay (SP142) for Atezolizumab. Appl Immunohistochem Mol Morphol. 2019;27:92–100. Martinez-Morilla, 2020, Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray, Lab Invest, 100, 4, 10.1038/s41374-019-0295-9 Gaule, 2017, A quantitative comparison of antibodies to programmed cell death 1 ligand 1, JAMA Oncol, 3, 256, 10.1001/jamaoncol.2016.3015 Lee, 2020, Concordance of programmed death-ligand 1 expression between SP142 and 22C3/SP263 assays in triple-negative breast cancer, J Breast Cancer, 23, 303, 10.4048/jbc.2020.23.e37 Torlakovic, 2020, “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy, Mod Pathol, 33, 4, 10.1038/s41379-019-0327-4 O'Malley, 2019, Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases, Mod Pathol, 32, 929, 10.1038/s41379-019-0210-3 Sun, 2016, Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies, J Transl Med, 14, 10.1186/s12967-016-0925-6 Rugo, 2019, LBA20—performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc analysis of IMpassion130, Ann Oncol, 30, v858, 10.1093/annonc/mdz394.009